Boston Scientific Corporation (NYSE:BSX), Natick, Mass., has
announced financial results for its first quarter ended March 31, 2004,
as well as preliminary information related to U.S. sales of its
TAXUS(TM) Express2(TM) paclitaxel-eluting coronary stent systems in
April.
Net sales for the first quarter were $1.082 billion as compared to
$807 million for the first quarter of 2003, an increase of 34 percent.
Excluding the favorable impact of $58 million of foreign currency
fluctuations, net sales were $1.024 billion, an increase of 27 percent.
Reported net income for the quarter increased 100 percent to $194
million, or $0.23 per share (diluted), as compared to $97 million, or
$0.11 per share, in the first quarter of 2003. Net income for the prior
year included net special charges of $20 million, or $0.03 per share.
The company received approval from the U.S. Food and Drug
Administration on March 4th to market its TAXUS system in the United
States, and it recorded its first commercial sale on March 8th. Net
sales of its TAXUS system in the United States for the first quarter
were $98 million. Worldwide net sales of all coronary stent systems
during the first quarter were $284 million, of which $216 million were
TAXUS systems.
"This quarter saw the achievement of a major milestone for
Boston Scientific with the successful launch of TAXUS in the U.S.,"
said Jim Tobin, president and CEO of Boston Scientific. "Our
rollout continues to proceed smoothly - with unconstrained supply - and
we continue to receive positive feedback from physicians on the
performance of this revolutionary technology. The successful launch of
TAXUS helped drive us to our first billion-dollar quarter, which was
marked by double-digit growth across all our businesses and
regions."
Boston Scientific is a worldwide developer, manufacturer and
marketer of medical devices whose products are used in a broad range of
interventional medical specialties.
The company discloses non-GAAP or pro forma financial information
that excludes certain items. Non-GAAP financial information may exclude
such items as charges related to purchased in-process research and
development and certain litigation. Management uses this financial
information to establish operational goals, and believes that non-GAAP
financial information may assist investors in analyzing the underlying
trends in the company's business over time. Investors should
consider this non-GAAP financial information in addition to, not as a
substitute for, or as superior to, financial information prepared in
accordance with GAAP.
For more information, call 508/650-8569 or visit
http://www.bostonscientific.com.
COPYRIGHT 2004 Worldwide
Videotex Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
Copyright 2004, Gale Group. All rights
reserved. Gale Group is a Thomson Corporation Company.
NOTE: All illustrations and photos have been removed from this article.